McCoy J G, Matta S G, Sharp B M
Endocrine Neurosciences Laboratories, Minneapolis Medical Research Foundation, MN 55404.
Neuroendocrinology. 1994 Oct;60(4):426-35. doi: 10.1159/000126777.
Interleukin-1 beta (IL-1 beta) is a potent ACTH secretagogue which activates the release of hypothalamic CRH. Direct injections of IL-1 beta into the hypothalamic median eminence (ME), a site which lacks a blood-brain barrier, has been shown to rapidly induce ACTH secretion. Therefore, the ME is a likely site whereby circulating IL-1 beta can access the brain to stimulate CRH and, consequently, ACTH secretion. To further evaluate this hypothesis, an angular stereotaxic approach was developed to localize the spread of IL-1 beta to the ME and to optimally separate the injectate from the hypothalamic paraventricular nucleus (PVN), another proposed site of IL-1 action. Studies of the diffusion of [125I]-IL beta (100 nl delivered over 60 s) showed that 97% remained within 200 microns of the ventral surface of the hypothalamus and 87% was contained within a radius of 550 microns of the injection site in the sagittal plane. Additional rats received recombinant human IL-1 beta (0.2-25.0 ng in 100 nl) into the ME (intra-ME). Plasma ACTH levels were significantly elevated by a much lower dose (0.5 ng, p < 0.001) of IL-1 beta than that previously reported. Responses appeared to be dose-dependent and ACTH was maximally stimulated by 2.0 ng IL-1 beta. Also, immunocytochemically labelled CRH in the ME was markedly depleted after intra-ME IL-1 beta. Indomethacin, an inhibitor of prostaglandin (PG) synthesis, has been shown to block both the induction of CRH secretion by IL-1 beta from hypothalamic explants, as well as the ACTH response to intravenous IL-1 beta. Thus, indomethacin was used to determine whether PGs are mediators of the ACTH response to IL-1 beta delivered into the ME. The ACTH response was abolished (p < 0.005) when a low dose of indomethacin (1 mg/kg i.v.) was administered 20 min before intra-ME IL-1 beta (25 ng). Finally, plasma ACTH was elevated in a dose-dependent manner by the intra-ME administration of PGs. The hierarchy of ACTH responses to PGE2 were: CSF < 0.5 micrograms (p < 0.001) = 2.0 micrograms < 4.0 micrograms (p < 0.05). Responses to PGF2 alpha were: CSF < 0.5 micrograms (p < 0.001) < 2.0 micrograms (p < 0.05) = 4.0 micrograms. Since these PGs appear to activate different second-messenger systems, a submaximal dose of each was administered alone or in combination.(ABSTRACT TRUNCATED AT 250 WORDS)
白细胞介素 -1β(IL -1β)是一种强效促肾上腺皮质激素释放激素(ACTH)分泌刺激物,可激活下丘脑促肾上腺皮质激素释放激素(CRH)的释放。已证明将IL -1β直接注射到缺乏血脑屏障的下丘脑正中隆起(ME)部位,能迅速诱导ACTH分泌。因此,ME可能是循环中的IL -1β进入大脑以刺激CRH从而促进ACTH分泌的部位。为进一步评估这一假说,开发了一种角度立体定位方法,以确定IL -1β扩散至ME的情况,并将注射物与下丘脑室旁核(PVN,另一个被认为是IL -1作用的部位)最佳分离。对[125I]-ILβ(60秒内注入100纳升)扩散的研究表明,97%保留在下丘脑腹侧表面200微米范围内,87%包含在矢状面注射部位半径550微米范围内。另外的大鼠在ME(ME内)接受重组人IL -1β(100纳升中含0.2 - 25.0纳克)。与先前报道相比,更低剂量(0.5纳克,p < 0.001)的IL -1β就能使血浆ACTH水平显著升高。反应似乎呈剂量依赖性,2.0纳克IL -1β对ACTH的刺激最大。同样,ME内注射IL -1β后,ME中免疫细胞化学标记的CRH明显减少。前列腺素(PG)合成抑制剂吲哚美辛已被证明可阻断下丘脑外植体中IL -1β诱导的CRH分泌以及对静脉注射IL -1β的ACTH反应。因此,使用吲哚美辛来确定PG是否是对注入ME的IL -1β产生ACTH反应的介质。在ME内注射IL -1β(25纳克)前20分钟静脉注射低剂量吲哚美辛(1毫克/千克)时,ACTH反应被消除(p < 0.005)。最后,ME内注射PG可使血浆ACTH呈剂量依赖性升高。对PGE2的ACTH反应分级为:脑脊液<0.5微克(p < 0.001) = 2.0微克<4.0微克(p < 0.05)。对PGF2α的反应为:脑脊液<0.5微克(p < 0.001)<2.0微克(p < 0.05) = 4.0微克。由于这些PG似乎激活不同的第二信使系统,因此分别单独或联合给予亚最大剂量的每种PG。(摘要截断于250字)